Stifel Nicolaus Raises Krystal Biotech (NASDAQ:KRYS) Price Target to $220.00

Krystal Biotech (NASDAQ:KRYS) had its target price lifted by Stifel Nicolaus from $204.00 to $220.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also recently weighed in on the company. Cantor Fitzgerald reaffirmed an overweight rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Evercore ISI upped their price target on Krystal Biotech from $201.00 to $206.00 and gave the stock an outperform rating in a research note on Monday, August 12th. Citigroup reaffirmed a neutral rating and issued a $204.00 price target (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. William Blair raised Krystal Biotech to a strong-buy rating in a research note on Friday, August 30th. Finally, Chardan Capital increased their target price on Krystal Biotech from $153.00 to $208.00 and gave the stock a buy rating in a research note on Monday, August 5th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of Buy and a consensus target price of $196.75.

Krystal Biotech Stock Performance

Shares of KRYS stock opened at $201.58 on Wednesday. Krystal Biotech has a fifty-two week low of $93.95 and a fifty-two week high of $219.34. The stock has a 50 day moving average price of $196.03 and a two-hundred day moving average price of $178.58. The company has a market capitalization of $5.79 billion, a P/E ratio of 107.80 and a beta of 0.82.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, August 5th. The company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.03. The company had revenue of $70.28 million during the quarter, compared to the consensus estimate of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The firm’s revenue for the quarter was up 70283900.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.25) earnings per share. As a group, equities analysts predict that Krystal Biotech will post 3.13 earnings per share for the current year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the sale, the insider now directly owns 1,500,882 shares of the company’s stock, valued at $296,814,424.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 14.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors have recently modified their holdings of the business. Jamison Private Wealth Management Inc. bought a new position in Krystal Biotech in the second quarter valued at about $28,000. GAMMA Investing LLC lifted its holdings in Krystal Biotech by 160.3% in the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after acquiring an additional 93 shares during the period. Key Financial Inc bought a new position in Krystal Biotech in the second quarter valued at about $28,000. Blue Trust Inc. lifted its holdings in Krystal Biotech by 2,328.6% in the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after acquiring an additional 163 shares during the period. Finally, Quest Partners LLC bought a new position in Krystal Biotech in the second quarter valued at about $71,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).